Welcome to Francis Academic Press

International Journal of Frontiers in Medicine, 2023, 5(5); doi: 10.25236/IJFM.2023.050510.

Correlation between “Qing Fei San Jie Wan” and key gene CTLA-4 in lung cancer


Zeyue Huo, Jiahao Fan, Yuan Hui

Corresponding Author:
Yuan Hui

Shaanxi University of Chinese Medicine, Xianyang, 712046, China


Lung cancer is the most threatening malignant tumor to the health and life of the population. In the past fifty years, the incidence and mortality of lung cancer have increased significantly, and Chinese residents are facing a serious burden of lung cancer. The co-inhibitory molecule CTLA-4 on the surface of T cells is a glycoprotein expressed on the surface of active CD4 and CD8 positive T cells, which transmits inhibitory signals to T cells, has the effect of down-regulating or terminating T cell activation, and participates in Negative regulation of the immune system. “QingFeiSanJieWan” has the effect of enhancing the function and effect of the immune system, which is of great significance to the human body's fight against lung cancer, and has a certain promoting effect on the activation of T cells and other lymphocytes. The drug has different inhibitory effects on the expression of co-inhibitory molecule CTLA-4 on the surface of CD4+ and CD8+ T cells. Preventing CTLA-4 and then inhibiting the immune response effect of T cells, thereby enhancing the immune function, fighting against lung cancer cell antigens in the body, and providing new immunological ideas for the treatment and drug mechanism of lung cancer. Using “QingFeiSanJieWan” to treat CTLA The anti-resistance effect of -4 proves that the drug is of great significance to the therapeutic mechanism of lung cancer.


“QingFeiSanJieWan”, CTLA-4, lung cancer gene, immune response

Cite This Paper

Zeyue Huo, Jiahao Fan, Yuan Hui. Correlation between “Qing Fei San Jie Wan” and key gene CTLA-4 in lung cancer. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 5: 59-62. https://doi.org/10.25236/IJFM.2023.050510.


[1] Cao Q, Rui G, Liang Y. Study on PM2. 5 pollution and the mortality due to lung cancer in China based on geographic weighted regression model[J]. BMC public health, 2018, 18(1): 1-10.

[2] Luo Y H, Luo L, Wampfler J A, et al. 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study[J]. The Lancet Oncology, 2019, 20(8): 1098-1108.

[3] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians, 2018, 68(6): 394-424.

[4] Carbone D P, Gandara D R, Antonia S J, et al. Non–small-cell lung cancer: role of the immune system and potential for immunotherapy[J]. Journal of Thoracic Oncology, 2015, 10(7): 974-984.

[5] Choudhury N, Nakamura Y. Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies[J]. Cancer ence, 2016, 107(2):107-115.

[6] Steven A, Fisher S A, Robinson B W. Immunotherapy for lung cancer[J]. Respirology. 2016, 21(5): 821-833.

[7] Goltz D, Gevensleben H, Vogt T J, et al. CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients[J]. JCI Insight, 2018, 3(13).

[8] Peggs K S, Quezada S A, Korman A J, et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.[J]. Current Opinion in Immunology, 2006, 18(2):206-213.

[9] Ribas A. Releasing the brakes on cancer immunotherapy[J]. N Engl J Med, 2015, 373(16): 1490-1492.

[10] Lemjabbar-Alaoui H, Hassan O U I, Yang Y W, et al. Lung cancer: Biology and treatment options [J]. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2015, 1856(2): 189-210.

[11] Yu J, Ji H, Liu A. Alcohol-soluble polysaccharide from Astragalus membranaceus: Preparation, characteristics and antitumor activity [J]. International journal of biological macromolecules, 2018, 118: 2057-2064.

[12] Tan W, Pan T, Wang S, et al. Immunometabolism modulation, a new trick of edible and medicinal plants in cancer treatment[J]. Food Chemistry, 2022, 376: 131860.

[13] Han H S, Shin J S, Song Y R, et al. Immunostimulatory effects of polysaccharides isolated from young barley leaves (Hordeum vulgare L.) with dual activation of Th1 and Th2 in splenic T cells and cyclophosphamide-induced immunosuppressed mice [J]. International journal of biological macromolecules, 2020, 147: 954-964.

[14] Loh X J, Young D J, Guo H, et al. Pearl powder—an emerging material for biomedical applications: A review [J]. Materials, 2021, 14(11): 2797.

[15] Zhang H, Xie W, Zhang Y, et al. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model [J]. Cancer Gene Therapy, 2022, 29(5): 456-465.